Author

Now showing items 1-1 of 1

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J.; Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J. (2004)

Objective: Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor ...